1460. Imipenem/Cilastatin (IMI)/Relebactam (REL) in Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia (HABP/VABP): Subgroup Analyses of Critically Ill Patients in the RESTORE-IMI 2 Trial

BACKGROUND: HABP/VABP are serious infections associated with high mortality. Critically ill patients (pts) are at particularly high risk of adverse clinical outcomes. In the RESTORE-IMI 2 trial, IMI/REL was non-inferior to PIP/TAZ in primary and key secondary endpoints. We evaluated outcomes specifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Luke F, Losada, Maria C, Mahoney, Kathryn A, Du, Jiejun, Brown, Michelle L, Tipping, Robert, Young, Katherine, DeRyke, C Andrew, Butterton, Joan R, Paschke, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777004/
http://dx.doi.org/10.1093/ofid/ofaa439.1641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777004/
http://dx.doi.org/10.1093/ofid/ofaa439.1641

Ejemplares similares